Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. freshman Avg
|
New words:
acre, Advisor, agitation, ago, Alcon, alter, Americo, Amgen, apixaban, Arca, AstraZeneca, ATRIPLA, Barr, biosimilar, blended, Brazilian, Bulgaria, calibration, Centre, CEO, clause, collusion, Congressional, contemplated, crime, CT, cytotoxic, dacarbazine, dapagliflozin, database, Deloitte, device, digit, disallowance, displayed, disrupt, distributorship, double, EFFERLAGAN, effervescent, eighteen, Eli, endpoint, enjoin, enjoined, enrollment, explanatory, fever, FTR, GLEEVEC, graph, Guidant, Guideline, Helmholtz, holder, Hybrid, hydrochlorothiazide, imatinib, immunoscience, implied, incapable, incompatible, Infektionsforschung, inflationary, input, Interbank, irrevocable, KENALOG, knowingly, Korean, land, learned, leaseback, legacy, Lilly, lock, lodged, LUMINITY, lymphoid, Majeure, Manati, Marchese, meslylate, mesylate, methotrexate, mg, Ministry, misled, misrepresented, Monte, multiemployer, myeloid, myloid, nonvested, NORVIR, NY, NYSE, Oakland, observed, obstruction, Ohio, onRating, operationally, output, overfunded, override, paracetamol, path, pathway, Pfizer, pivotal, placement, pledge, pledged, PMDA, point, pre, precipitously, premium, quantify, quantifying, radiation, rehearing, remeasurement, renminbi, renovate, repayment, resistance, Ritonavir, Romania, Rowan, RxUSA, Sampson, Sandoz, securitized, seller, Sherman, simulation, specialist, SPRYCEL, Starkman, Stephenson, steroid, Sun, Synthon, tabular, taxpayer, TechneLite, technique, thromboembolic, timeframe, Touche, Tribunal, TRICARE, TRIZIVIR, TRx, tyrosine, unlawful, unqualified, UNRESOLVED, untreated, unwind, upheld, variance, Weisz, welfare, wrongly, Zentrum
Removed:
accretion, ACE, actuarially, advisory, agonist, Alabama, Anthony, anticompetitive, Arizona, autoimmune, Bodnar, Botanical, Bush, BUSPAR, challenging, close, closed, coated, commerce, compendia, comprise, conflict, Connecticut, consolidate, continent, correct, corrected, declined, deficiency, deliver, deploy, dictated, disproportionate, disseminated, Dixon, downsize, downsizing, EITF, Energy, enteric, essentially, EXCEDRIN, false, falsely, FAS, FTC, grew, Heimbold, Hooper, House, Howson, immune, improperly, indemnify, inside, Intercontinental, involvement, ischemic, Jr, losing, master, McGoldrick, metabolic, metformin, Mississippi, Montana, Nevada, NS, older, overstating, phenylpropanolamine, pioneer, PPA, PPAR, pretrial, profile, promise, published, PwC, readily, recover, reorganization, reorganized, restitution, Ringrose, secondary, separation, setting, settled, sNDA, solution, STADOL, staffing, statin, stretch, subordinated, subpoena, subsidy, sufficiently, Tamar, Treasurer, treble, tubulin, varied, VIDEX, VIE, vitamin, Weizmann, Wendy, West, workdown
Filing tables
Filing exhibits
- 10-K Annual report
- 10 Bristol-myers Squibb Company 2002 Stock Incentive Plan
- 10 Form of Agreement
- 10 Form of Performance Shares Agreement
- 10 Form of Restricted Stock Units Agreement
- 12 Statement Re Computation of Ratios
- 21 Subsidiaries of the Registrant
- 23 Consent of Deloitte & Touche LLP
- 23 Consent of Pricewaterhousecoopers LLP
- 31 Section 302 Certification Letter
- 31 Section 302 Certification Letter
- 32 Section 906 Certification Letter
- 32 Section 906 Certification Letter
Related press release
BMY similar filings
Filing view
External links
EXHIBIT 23b.
Consent of Independent Registered Public Accounting Firm
We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (Nos. 33-30856, 33-38411, 33-38587, 33-44788, 333-47403, 33-52691, 33-30756-02, 33-58187, 333-02873, 333-65424 and 333-107414) and Form S-3 (Nos. 33-33682, 33-62496, 333-114107 and 333-117818) of Bristol-Myers Squibb Company of our report dated March 13, 2006 relating to the financial statements and financial statement schedule, which appears in this Form 10-K.
/s/ PricewaterhouseCoopers LLP
PricewaterhouseCoopers LLP
Philadelphia, PA
February 26, 2007
E-23-2